M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 54.32 USD 4.74% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
MoonLake Immunotherapeutics?
Write Note

MoonLake Immunotherapeutics
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MoonLake Immunotherapeutics
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
M
MoonLake Immunotherapeutics
NASDAQ:MLTX
Income from Continuing Operations
-$44.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Income from Continuing Operations
-$234.5m
CAGR 3-Years
2%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Income from Continuing Operations
-CHf39.9m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Income from Continuing Operations
-$239.6m
CAGR 3-Years
N/A
CAGR 5-Years
-84%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Income from Continuing Operations
-CHf69.1m
CAGR 3-Years
1%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Xlife Sciences AG
SIX:XLS
Income from Continuing Operations
CHf9.3m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MoonLake Immunotherapeutics
Glance View

Market Cap
3.4B USD
Industry
N/A

MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

MLTX Intrinsic Value
7.72 USD
Overvaluation 86%
Intrinsic Value
Price
M

See Also

What is MoonLake Immunotherapeutics's Income from Continuing Operations?
Income from Continuing Operations
-44.1m USD

Based on the financial report for Dec 31, 2023, MoonLake Immunotherapeutics's Income from Continuing Operations amounts to -44.1m USD.

What is MoonLake Immunotherapeutics's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
32%

Over the last year, the Income from Continuing Operations growth was 32%.

Back to Top